NCT06439056View on ClinicalTrials.gov

Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 27, 2024

Primary Completion Date

July 18, 2025

Study Completion Date

July 18, 2025

Conditions
Type 2 Diabetes
Interventions
DRUG

NEX-22A, a prolonged release formulation of liraglutide

NEX-22A, a prolonged release formulation of liraglutide

Trial Locations (1)

41460

Profil, Neuss

Sponsors

Lead Sponsor

Nanexa AB
All Listed Sponsors
collaborator

Profil Institut für Stoffwechselforschung GmbH

INDUSTRY

lead

Nanexa AB

INDUSTRY

NCT06439056 - Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D | Biotech Hunter | Biotech Hunter